Viewing nowCombinationSebiduo HCT Tablet 5/20/12.5 Milligrams
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.

MFDS item code 201805265 · Approved 2018.12.26 · Insurance code 645405450
Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy
This is a suitable treatment for patients with essential hypertension whose blood pressure is not adequately controlled even with the combined use of amlodipine and olmesartan medoxomil. This combination helps to dilate blood vessels and lower blood pressure, reducing the burden on the heart and blood vessels. It can be especially used when monotherapy is insufficient to manage blood pressure effectively. This contributes to reducing the risk of cardiovascular complications and improving the overall health status of patients. Therefore, it is used for blood pressure control in essential hypertension.
Take 1 tablet once daily with water, regardless of meals. It is recommended that you take it at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose of each individual component (amlodipine and olmesartan medoxomil as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy with amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation chart. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Hepatic impairment Use with caution in patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. Blood pressure should be monitored closely and more frequently in older adults. Because experience with this medicine in older adults, particularly those aged 75 years and older, is very limited, monitor very carefully during treatment.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy. Therefore, it should be stopped immediately upon confirmation of pregnancy. Patients with allergies to this drug or its components, or those with certain heart, kidney, or liver diseases, should not take this medication. It may be dangerous to use this drug in cases of severely low blood pressure, acute heart failure, or severe kidney or liver dysfunction. Patients with decreased blood volume or electrolyte imbalances should be closely monitored for hypotension when starting this medication. This drug may affect kidney function, so patients with kidney problems or severe heart failure should regularly have blood tests to check kidney function and electrolyte levels. Patients with liver disease, especially those with progressive liver cirrhosis, require careful monitoring when taking this medication. Patients with eye diseases, particularly acute angle-closure glaucoma, should be cautious as some components of this medication may exacerbate symptoms. This drug may interact with certain medications, increasing the risk of side effects when taken with lithium, some analgesics, or other antihypertensives; therefore, consultation with healthcare professionals is essential. Dizziness, headaches, edema, gastrointestinal disturbances, and other side effects may occur during treatment, and any unusual symptoms should be reported immediately. This medication is also available for elderly patients; however, as there may be decreased kidney or liver function, it is recommended to start at lower doses and monitor closely. Overdose may lead to severe hypotension or arrhythmias; therefore, adherence to dosage is vital, and if symptoms occur, immediate medical attention is necessary. This medication should be stored in a tightly sealed container away from direct sunlight and moisture, out of reach of children, and it is advised not to change the container arbitrarily. If breastfeeding, it is recommended to discontinue either breastfeeding or this medication as the components may pass into breast milk. The safety and efficacy of this medication have not been established in children under 18 years of age, so its use is not recommended.
Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disorder, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremors, visual disturbances, reduced tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmias, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, abdominal distention, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, hair loss, vascular edema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, vesicular pustulosis, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, angioedema, rash, recurrence of skin lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle cramp, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urinary frequency, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, weakness, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, elevated serum creatinine, elevated serum urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, eczema, limb pain, mild decrease in mean hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome, choroidal exudate
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and light, at temperatures between 1 degree and 30 degrees Celsius. Proper storage will maintain the effectiveness of the medication and ensure safe use.
White and orange round film-coated tablet
28 tablets (14 tablets/PTPX2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.